ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)GlobeNewsWire • 12/21/20
ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/10/20
ChemoCentryx Reports Third Quarter 2020 Financial Results and Recent HighlightsGlobeNewsWire • 11/09/20
ChemoCentryx Announces Plenary Session at ACR Convergence 2020 to Highlight Findings of ADVOCATE Phase III Trial in ANCA-Associated VasculitisGlobeNewsWire • 11/06/20
ChemoCentryx and VFMCRP announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopanGlobeNewsWire • 11/03/20
ChemoCentryx to Hold Third Quarter 2020 Financial Results Conference Call on Monday, November 9, 2020GlobeNewsWire • 11/02/20
ChemoCentryx Announces Positive Topline Results of Phase II AURORA Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS)GlobeNewsWire • 10/28/20
ChemoCentryx Announces FDA Acceptance of the Avacopan New Drug Application (NDA) for the Treatment of ANCA-Associated VasculitisGlobeNewsWire • 09/17/20
ChemoCentryx to Present at the H.C. Wainwright 22nd Annual Global Investment ConferenceGlobeNewsWire • 09/08/20
ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/11/20
ChemoCentryx Reports Second Quarter 2020 Financial Results and Recent HighlightsGlobeNewsWire • 08/10/20
ChemoCentryx to Hold Second Quarter 2020 Financial Results Conference Call on Monday, August 10, 2020GlobeNewsWire • 08/03/20
Earnings Preview: ChemoCentryx (CCXI) Q2 Earnings Expected to DeclineZacks Investment Research • 07/27/20
ChemoCentryx Submits New Drug Application to the U.S. FDA for Avacopan in ANCA-Associated VasculitisGlobeNewsWire • 07/09/20
ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer TreatmentGlobeNewsWire • 06/24/20
ChemoCentryx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 06/15/20